QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
Log in
NASDAQ:ICCC

ImmuCell Stock Forecast, Price & News

$5.96
-0.26 (-4.18 %)
(As of 12/1/2020 12:00 AM ET)
Add
Compare
Today's Range
$5.90
Now: $5.96
$6.20
50-Day Range
$5.21
MA: $5.66
$6.23
52-Week Range
$3.70
Now: $5.96
$8.13
Volume19,106 shs
Average Volume37,570 shs
Market Capitalization$43.02 million
P/E RatioN/A
Dividend YieldN/A
Beta1.09
ImmuCell Corporation, an animal health company, acquires, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was founded in 1982 and is headquartered in Portland, Maine.

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ICCC
CUSIPN/A
Phone207-878-2770
Employees51

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$13.72 million
Cash Flow$0.14 per share
Book Value$3.88 per share

Profitability

Net Income$-1,300,000.00

Miscellaneous

Market Cap$43.02 million
Next Earnings Date2/16/2021 (Estimated)
OptionableNot Optionable
$5.96
-0.26 (-4.18 %)
(As of 12/1/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ICCC News and Ratings via Email

Sign-up to receive the latest news and ratings for ICCC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ImmuCell (NASDAQ:ICCC) Frequently Asked Questions

How has ImmuCell's stock price been impacted by COVID-19 (Coronavirus)?

ImmuCell's stock was trading at $4.30 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ICCC stock has increased by 38.7% and is now trading at $5.9643.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of ImmuCell?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmuCell in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ImmuCell
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than ImmuCell?

Wall Street analysts have given ImmuCell a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ImmuCell wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is ImmuCell's next earnings date?

ImmuCell is scheduled to release its next quarterly earnings announcement on Tuesday, February 16th 2021.
View our earnings forecast for ImmuCell
.

How were ImmuCell's earnings last quarter?

ImmuCell Co. (NASDAQ:ICCC) posted its quarterly earnings results on Thursday, November, 19th. The biotechnology company reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.04. ImmuCell had a negative net margin of 9.99% and a negative return on equity of 5.32%.
View ImmuCell's earnings history
.

What guidance has ImmuCell issued on next quarter's earnings?

ImmuCell issued an update on its third quarter 2020 Pre-Market earnings guidance on Tuesday, October, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $3.7-3.7 million, compared to the consensus revenue estimate of $3.27 million.

What price target have analysts set for ICCC?

1 Wall Street analysts have issued 12-month price objectives for ImmuCell's stock. Their forecasts range from $14.00 to $14.00. On average, they expect ImmuCell's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 134.7% from the stock's current price.
View analysts' price targets for ImmuCell
.

Are investors shorting ImmuCell?

ImmuCell saw a increase in short interest in November. As of November 15th, there was short interest totaling 3,600 shares, an increase of 50.0% from the October 31st total of 2,400 shares. Based on an average daily trading volume, of 8,500 shares, the short-interest ratio is currently 0.4 days. Approximately 0.1% of the company's stock are short sold.
View ImmuCell's Short Interest
.

Who are some of ImmuCell's key competitors?

What other stocks do shareholders of ImmuCell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuCell investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Agile Therapeutics (AGRX), Biocept (BIOC), Amarin (AMRN), CorMedix (CRMD), CRISPR Therapeutics (CRSP), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA) and Pfizer (PFE).

Who are ImmuCell's key executives?

ImmuCell's management team includes the following people:
  • Mr. Michael F. Brigham, Pres, CEO, Principal Financial Officer, Treasurer, Sec. & Director (Age 59, Pay $344.03k)
  • Dr. Joseph H. Crabb Ph.D., VP & Chief Scientific Officer (Age 65, Pay $53.38k)
  • Ms. Bobbi Jo Brockmann, VP of Sales & Marketing and Director (Age 43, Pay $289.91k)
  • Ms. Elizabeth L. Williams, VP of Manufacturing Operations (Age 64, Pay $251.59k)
  • Elizabeth S. Toothaker, Director of Fin. & Admin.
  • Mr. A. Gustavo Scaffa, Sr. Director of Quality
  • John W. Zinckgraf, Director of Product Devel.

What is ImmuCell's stock symbol?

ImmuCell trades on the NASDAQ under the ticker symbol "ICCC."

Who are ImmuCell's major shareholders?

ImmuCell's stock is owned by many different retail and institutional investors. Top institutional shareholders include Essex Financial Services Inc. (0.28%). Company insiders that own ImmuCell stock include David Cunningham and David Scott Tomsche.
View institutional ownership trends for ImmuCell
.

Which institutional investors are buying ImmuCell stock?

ICCC stock was purchased by a variety of institutional investors in the last quarter, including Essex Financial Services Inc.. Company insiders that have bought ImmuCell stock in the last two years include David Cunningham, and David Scott Tomsche.
View insider buying and selling activity for ImmuCell
.

How do I buy shares of ImmuCell?

Shares of ICCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ImmuCell's stock price today?

One share of ICCC stock can currently be purchased for approximately $5.96.

How big of a company is ImmuCell?

ImmuCell has a market capitalization of $43.02 million and generates $13.72 million in revenue each year. The biotechnology company earns $-1,300,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. ImmuCell employs 51 workers across the globe.

What is ImmuCell's official website?

The official website for ImmuCell is www.immucell.com.

How can I contact ImmuCell?

ImmuCell's mailing address is 56 EVERGREEN DR, PORTLAND ME, 04103. The biotechnology company can be reached via phone at 207-878-2770 or via email at [email protected]

This page was last updated on 12/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.